Kutane Nebenwirkungen unter Immun-Checkpoint-Inhibitor-Therapie

Zusammenfassung

Moderne Immuntherapeutika wie Nivolumab, Pembrolizumab oder Ipilimumab, die sogenannte Immun-Checkpoints blockieren, haben die onkologische Therapie in den letzten Jahren revolutioniert. Mit dem neuen Wirkmechanismus der Blockade wichtiger Kontrollpunkte im Immunsystem zeigen sich jedoch auch eine Vielzahl an unterschiedlichen Nebenwirkungen. Diese treten nicht selten an der Haut auf. Zu den häufigsten dermalen Reaktionen unter Immuntherapie zählen die Vitiligo, Exantheme, blasenbildende Reaktionen oder der Lichen planus. Ausgeprägter Juckreiz kann Patienten stark beeinträchtigen. Der Verlauf bei auf die Haut beschränkten Nebenwirkungen ist häufig mild und gut zu behandeln oder selbstlimitierend. Hauterscheinungen können jedoch auch als Symptom systemischer Reaktionen auftreten. Eine frühe Diagnosestellung, die Einleitung einer adäquaten Therapie sowie eine interdisziplinäre Betreuung bei komplexen Erkrankungen sind entscheidend, um dauerhafte Einschränkungen für die Patienten zu verhindern und eine sichere Behandlung der zugrundeliegenden Tumorerkrankung gewährleisten zu können.

Abstract

Modern immunotherapies such as nivolumab, pembrolizumab or ipilimumab have profoundly changed oncological therapy in recent years. With this new mechanism of action of blocking important checkpoints of the immune system, however, a large number of different adverse effects have become apparent and the skin is frequently involved. The most common dermal reactions related to immune-checkpoint inhibition include vitiligo, exanthema, blistering reactions or lichen planus. Pronounced itching can greatly affect patients’ quality of life. The course of cutaneous reactions is often mild and therapy is uncomplicated, or events are self-limiting. However, skin reactions can also occur as a symptom of systemic reactions. An early diagnosis, initiation of adequate therapies as well as an interdisciplinary approach in complex situations are crucial to prevent permanent impairments for patients and to assure safe treatment of the underlying malignancy.

Schlüsselwörter

Immuntherapie - Hautreaktion - PD-1-Inhibitor - Exanthem

Key words

immunotherapy - skin reaction - PD-1-inhibitor - exanthema

Publikationsverlauf

Artikel online veröffentlicht:
11. August 2022

• Literatur

• 1 Patel AB, Farooq S, Welborn M. et al. Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit. Cancer 2021;
• 2 Sibaud V. Dermatologic Reactions to Immune Checkpoint Inhibitors: Skin Toxicities and Immunotherapy. Am J Clin Dermatol 2018; 19: 345-361
• 3 Hassel JC, Heinzerling L, Aberle J. et al. Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. Cancer Treat Rev 2017; 57: 36-49
• 4 Sibaud V, Meyer N, Lamant L. et al. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol 2016; 28: 254-263
• 5 Mineiro Dos Santos Garrett NF, Carvalho da Costa AC, Barros Ferreira E. et al. Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis. PLoS One 2021; 16: e0255716
• 6 Ito J, Fujimoto D, Nakamura A. et al. Aprepitant for refractory nivolumab-induced pruritus. Lung Cancer 2017; 109: 58-61
• 7 Burgos-San Jose A, Colomer-Aguilar C, Martinez-Caballero D. et al. Effectiveness and safety of atezolizumab, nivolumab and pembrolizumab in metastatic non-small cell lung cancer. Farm Hosp 2021; 45: 121-125
• 8 Hua C, Boussemart L, Mateus C. et al. Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. JAMA Dermatol 2016; 152: 45-51
• 9 Larsabal M, Marti A, Jacquemin C. et al. Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo. J Am Acad Dermatol 2017; 76: 863-870
• 10 Nakamura Y, Tanaka R, Asami Y. et al. Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study. J Dermatol 2017; 44: 117-122
• 11 Freeman-Keller M, Kim Y, Cronin H. et al. Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes. Clin Cancer Res 2016; 22: 886-894
• 12 Abdel-Rahman O, ElHalawani H, Fouad M. Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis. Future Oncol 2015; 11: 2471-2484
• 13 Pospischil I, Hoetzenecker W. Arzneimittelexantheme unter modernen zielgerichteten Therapien - Immuncheckpoint- und EGFR-Inhibitoren. J Dtsch Dermatol Ges 2021; 19: 1621-1645
• 14 Heinzerling L, de Toni EN, Schett G. et al. Checkpoint Inhibitors. Dtsch Arztebl Int 2019; 116: 119-126
• 15 Chen CB, Wu MY, Ng CY. et al. Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies. Cancer Manag Res 2018; 10: 1259-1273
• 16 Tetzlaff MT, Nagarajan P, Chon S. et al. Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features. Am J Dermatopathol 2017; 39: 121-129
• 17 Shi VJ, Rodic N, Gettinger S. et al. Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy. JAMA Dermatol 2016; 152: 1128-1136
• 18 Ellis SR, Vierra AT, Millsop JW. et al. Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features. J Am Acad Dermatol 2020; 83: 1130-1143
• 19 Wakade DV, Carlos G, Hwang SJ. et al. PD-1 inhibitors induced bullous lichen planus-like reactions: a rare presentation and report of three cases. Melanoma Res 2016; 26: 421-424
• 20 Larkin J, Chiarion-Sileni V, Gonzalez R. et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015; 373: 23-34
• 21 Abdel-Wahab N, Suarez-Almazor M. Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy. Rheumatology 2019; 58: vii40-vii48 doi:
• 22 Chorti E, Kanaki T, Zimmer L. et al. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis. Eur J Cancer 2020; 131: 18-26
• 23 Dimitriou F, Frauchiger AL, Urosevic-Maiwald M. et al. Sarcoid-like reactions in patients receiving modern melanoma treatment. Melanoma Res 2018; 28: 230-236
• 24 Gran F, Weber J, Schummer P. et al. Sarcoidosis developing upon immune checkpoint inhibition in advanced uveal melanoma. Eur J Dermatol 2020; 30: 629-631
• 25 Tan I, Malinzak M, Salama AKS. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy. J Immunother Cancer 2018; 6: 77
• 26 Lopez AT, Khanna T, Antonov N. et al. A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors. Int J Dermatol 2018; 57: 664-669
• 27 Gran F, Goebeler M, Gesierich A. Bullous pemphigoid developing upon immune checkpoint inhibition with nivolumab. Eur J Dermatol 2019; 29: 448-449
• 28 Haug V, Behle V, Benoit S. et al. Pembrolizumab-associated mucous membrane pemphigoid in a patient with Merkel cell carcinoma. Br J Dermatol 2018; 179: 993-994
• 29 Siegel J, Totonchy M, Damsky W. et al. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. J Am Acad Dermatol 2018; 79: 1081-1088
• 30 Sadik CD, Langan EA, Gratz V. et al. Checkpoint Inhibition May Trigger the Rare Variant of Anti-LAD-1 IgG-Positive, Anti-BP180 NC16A IgG-Negative Bullous Pemphigoid. Front Immunol 2019; 10: 1934
• 31 Sadik CD, Langan EA, Gutzmer R. et al. Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated Cases of Bullous Pemphigoid From Six German Dermatology Centers. Front Immunol 2020; 11: 588582
• 32 Sowerby L, Dewan AK, Granter S. et al. Rituximab Treatment of Nivolumab-Induced Bullous Pemphigoid. JAMA Dermatol 2017; 153: 603-605
• 33 Braun GS, Kirschner M, Rubben A. et al. Side effects of novel cancer immunotherapies. Nephrologe 2020; 1-13
• 34 Maloney NJ, Ravi V, Cheng K. et al. Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review. Int J Dermatol 2020; 59: e183-e188
• 35 Rambeck B, Wolf P. Lamotrigine. clinical pharmacokinetics. Clin Pharmacokinet 1993; 25: 433-443
• 36 Delanoy N, Michot JM, Comont T. et al. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematol 2019; 6: e48-e57
• 37 Shiuan E, Beckermann KE, Ozgun A. et al. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. J Immunother Cancer 2017; 5: 8
• 38 Hasegawa T, Ozaki Y, Inoue T. et al. Nivolumab-related severe thrombocytopenia in a patient with relapsed lung adenocarcinoma: a case report and review of the literature. J Med Case Rep 2019; 13: 316
• 39 Godel P, Shimabukuro-Vornhagen A, von Bergwelt-Baildon M. Understanding cytokine release syndrome. Intensive Care Med 2018; 44: 371-373
• 40 Ceschi A, Noseda R, Palin K. et al. Immune Checkpoint Inhibitor-Related Cytokine Release Syndrome: Analysis of WHO Global Pharmacovigilance Database. Front Pharmacol 2020; 11: 557
• 41 Shimabukuro-Vornhagen A, Godel P, Subklewe M. et al. Cytokine release syndrome. J Immunother Cancer 2018; 6: 56
• 42 Lee DW, Gardner R, Porter DL. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014; 124: 188-195
• 43 Eichenauer DA, Lachmann G, La Rosee P. [Hemophagocytic lymphohistiocytosis in critically ill patients]. Med Klin Intensivmed Notfmed 2021; 116: 129-134
• 44 Allen CE, Yu X, Kozinetz CA. et al. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2008; 50: 1227-1235
• 45 Richter MD, Crowson C, Kottschade LA. et al. Rheumatic Syndromes Associated With Immune Checkpoint Inhibitors: A Single-Center Cohort of Sixty-One Patients. Arthritis Rheumatol 2019; 71: 468-475
• 46 Betrains AE, Blockmans DE. Immune Checkpoint Inhibitor-Associated Polymyalgia Rheumatica/Giant Cell Arteritis Occurring in a Patient After Treatment With Nivolumab. J Clin Rheumatol 2021; 27: S555-S556
• 47 Pugh D, Karabayas M, Basu N. et al. Large-vessel vasculitis. Nat Rev Dis Primers 2022; 7: 93
• 48 Watanabe R, Berry GJ, Liang DH. et al. Pathogenesis of Giant Cell Arteritis and Takayasu Arteritis-Similarities and Differences. Curr Rheumatol Rep 2020; 22: 68
• 49 Simon S, Ninan J, Hissaria P. Diagnosis and management of giant cell arteritis: Major review. Clin Exp Ophthalmol 2021; 49: 169-185
• 50 Ge Y, Zhang H, Weygant N. et al. Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials. Front Pharmacol 2021; 12: 640099